168 related articles for article (PubMed ID: 37559343)
1. Semimechanistic pharmacokinetic-pharmacodynamic model of tripegfilgrastim for pediatric patients after chemotherapy.
Lee S; Hong KT; Jang IJ; Yu KS; Kang HJ; Oh J
CPT Pharmacometrics Syst Pharmacol; 2023 Sep; 12(9):1319-1334. PubMed ID: 37559343
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and Pharmacodynamic Characteristics of Tripegfilgrastim, a Pegylated G-CSF, in Pediatric Patients with Solid Tumors.
Lee S; Hong KT; Moon SJ; Choi JY; Hong CR; Shin HY; Cho JY; Jang IJ; Yu KS; Oh J; Kang HJ
Clin Pharmacol Ther; 2022 Jan; 111(1):293-301. PubMed ID: 34605552
[TBL] [Abstract][Full Text] [Related]
3. Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach.
Macaire P; Paris J; Vincent J; Ghiringhelli F; Bengrine-Lefevre L; Schmitt A
Br J Clin Pharmacol; 2020 Dec; 86(12):2473-2485. PubMed ID: 32386071
[TBL] [Abstract][Full Text] [Related]
4. High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study.
Rowinsky EK; Baker SD; Burks K; O'Reilly S; Donehower RC; Grochow LB
Ann Oncol; 1998 Feb; 9(2):173-80. PubMed ID: 9553662
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.
Kang KW; Lee BH; Jeon MJ; Yu ES; Kim DS; Lee SR; Sung HJ; Choi CW; Park Y; Kim BS
Cancer Med; 2020 Sep; 9(17):6102-6110. PubMed ID: 32633471
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of pegfilgrastim.
Yang BB; Kido A
Clin Pharmacokinet; 2011 May; 50(5):295-306. PubMed ID: 21456630
[TBL] [Abstract][Full Text] [Related]
7. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
Cairo MS; Shen V; Krailo MD; Bauer M; Miser JS; Sato JK; Blatt J; Blazar BR; Frierdich S; Liu-Mares W; Reaman GH
J Pediatr Hematol Oncol; 2001 Jan; 23(1):30-8. PubMed ID: 11196267
[TBL] [Abstract][Full Text] [Related]
8. Justification for a Fixed Dose of Eflapegrastim, a Long-Acting G-CSF, in Patients Receiving Docetaxel-Cyclophosphamide Chemotherapy.
Barrett JA; Greene D; Lakshmikanthan S; Kolli P; Chawla S; Lebel F
J Clin Pharmacol; 2021 Feb; 61(2):204-210. PubMed ID: 32827162
[TBL] [Abstract][Full Text] [Related]
9. Biological and clinical correlates after chemotherapy and granulocyte colony-stimulating factor administration.
Higa GM; DeVore RF; Auber ML; Lynch JP; Landreth KS
Pharmacotherapy; 1998; 18(1):1-8. PubMed ID: 9469674
[TBL] [Abstract][Full Text] [Related]
10. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I
J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696
[TBL] [Abstract][Full Text] [Related]
11. Effects of Prophylactic Administration of Granulocyte Colony-Stimulating Factor on Peripheral Leukocyte and Neutrophil Counts Levels After Chemotherapy in Patients With Early-Stage Breast Cancer: A Retrospective Cohort Study.
Tian W; Wang Y; Zhou Y; Yao Y; Deng Y
Front Oncol; 2022; 12():777602. PubMed ID: 35547875
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic-pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia.
Melhem M; Delor I; Pérez-Ruixo JJ; Harrold J; Chow A; Wu L; Jacqmin P
Br J Clin Pharmacol; 2018 May; 84(5):911-925. PubMed ID: 29318653
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
Shi YK; He XH; Yang S; Wang HQ; Jiang ZF; Zhu YZ; Ke XY; Zhang Y; Liu YP; Zhang WJ; Wang Z; Shi QZ; Xie XD; Zhang HL; Wang JJ; Luo DY; Zheng QS; Sun RY
Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3414-9. PubMed ID: 17313855
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats.
Nohynek GJ; Plard JP; Wells MY; Zerial A; Roquet F
Cancer Chemother Pharmacol; 1997; 39(3):259-66. PubMed ID: 8996530
[TBL] [Abstract][Full Text] [Related]
15. Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach.
Reda M; Macaire P; Bellio H; Uwer L; Ilie S; Lorgis V; Hennequin A; Ladoire S; Rederstorff E; Fumoleau P; Isambert N; Bonnin N; You B; Freyer G; Desmoulins I; Schmitt A
Cancer Chemother Pharmacol; 2022 Feb; 89(2):197-208. PubMed ID: 34997290
[TBL] [Abstract][Full Text] [Related]
16. An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects.
Shin KH; Lim KS; Lee H; Jang IJ; Yu KS
Invest New Drugs; 2014 Aug; 32(4):636-43. PubMed ID: 24468886
[TBL] [Abstract][Full Text] [Related]
17. Disposition of recombinant human granulocyte colony-stimulating factor in children with severe chronic neutropenia.
Kearns CM; Wang WC; Stute N; Ihle JN; Evans WE
J Pediatr; 1993 Sep; 123(3):471-9. PubMed ID: 7689097
[TBL] [Abstract][Full Text] [Related]
18. Randomized study of dose or schedule modification of granulocyte colony-stimulating factor in platinum-based chemotherapy for elderly patients with lung cancer.
Oshita F; Yamada K; Nomura I; Tanaka G; Ikehara M; Noda K
Oncol Rep; 2001; 8(4):861-6. PubMed ID: 11410799
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetic-Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin.
Fernández-Teruel C; Lubomirov R; Fudio S
J Clin Pharmacol; 2021 Sep; 61(9):1206-1219. PubMed ID: 33914350
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
Yang S; Shi YK; Liu P; Han XH; He XH; Cai YM; Chen ZM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
